Diabetes: Prescribing of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2 inhibitors) and risk of Diabetic Ketoacidosis (including in patients with COVID-19) (APC Approved)
-
Due for review31 August 2025
Do you want to add this to your CPD record?
Did you find this page helpful?